Distribution of antigenic aberration in the bone marrow of acute leukemia in complete remission

• Published in: Taehan Chindan Kŏmsa Ŭihakhoe chi 2008-02, Vol.28 (1), p.1-7
• Main Authors: Shin, Soyoung, Kahng, Jimin, Kim, Myungshin, Lim, Jihyang, Kim, Younggoo, Han, Kyungja
• Format: Article
• Language: Korean
• Subjects: Acute Disease; Antigens, CD - metabolism; Antigens, CD19 - metabolism; Antigens, CD20 - metabolism; Antigens, CD34 - metabolism; Antigens, Differentiation, Myelomonocytic - analysis; Antigens, Differentiation, Myelomonocytic - metabolism; Biomarkers, Tumor - immunology; Bone Marrow Cells - classification; Bone Marrow Cells - metabolism; Flow Cytometry; Hematopoietic Stem Cells - classification; Hematopoietic Stem Cells - metabolism; Humans; Immunophenotyping; Leukemia - diagnosis; Leukemia - drug therapy; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - drug therapy; Neoplasm, Residual; Remission Induction
• ISSN: 1598-6535
• DOI: 10.3343/kjlm.2008.28.1.1

The aberrant, leukemia-associated antigen expression patterns allow us to discriminate leukemic blasts from normal precursor cells. Our major goal was to determine a guideline for the detection of minimal residual disease using CD20+/CD34+ and myeloid Ag+/CD19+ combination in the bone marrow of acute leukemia in complete remission (CR) after chemotherapy. Bone marrow samples from 117 patients with acute leukemia in complete remission after chemotherapy and from 22 healthy controls were immunophenotyped by triple staining and measured by flow cytometry. The CD20+/CD34+ cells in the large lymphocyte gate (R1) ranged from 0% to 3.% (0.8plusmn;0.82%, P=0.000) in CD20+/CD34+ B-lineage ALL CR (N=31), from 0.03% to 4.2% (0.7plusmn;0.83%, P=0.000) in CD20-/CD34- B-lineage ALL CR (N=66), from 0.1% to 0.96% (0.45plusmn;0.32%, P=0.016) in T-ALL CR (N=10), and from 0.02% to 0.48% (0.18plusmn;0.15%, P=0.776) in AML CR (N=10). The CD13,33+/CD19+ cells in R1 gate ranged from 0% to 2.69% (0.37plusmn;0.48%, P